KEY DETAILS
Jim Cramer flagged Eli Lilly's GLP-1 growth as reason to view LLY as a core stock to own.
CMS says it will audit Part D plans to catch any that reverse GLP-1 claims to shift members into the $50 Bridge program.
Novo Nordisk suffered a data breach traced to stolen GitHub access tokens.
Analysts are debating whether weight-loss drugs or AI will reshape the economy first.
New research explores whether Ozempic use has any connection to hair loss.
Jim Cramer highlighted Eli Lilly today, pointing to its GLP-1 growth as the reason he now considers the stock a core holding. That comment landed alongside a more cautionary signal from CMS, which says it will audit Part D plans to catch any that shift members into the $50 Medicare GLP-1 Bridge program. A Novo Nordisk data breach tied to stolen GitHub tokens rounds out a day that mixed market enthusiasm with real operational risk.
Cramer's comments today framed Eli Lilly's tirzepatide-driven growth, from Zepbound and Mounjaro, as durable enough to make LLY a stock investors should hold regardless of short-term swings in the broader market. He described the company as a dependable holding investors can build a portfolio around, arguing that the underlying demand for GLP-1 drugs gives Lilly growth other companies in the sector cannot easily match. His confidence rests on the assumption that demand keeps climbing and that Lilly can keep supplying it. That assumption is about to be tested by a different kind of scrutiny than Wall Street usually applies.
CMS says its program integrity audits will review Part D plans, including how often they delete prescription drug claims, to catch plans that push members into the $50 Medicare GLP-1 Bridge program. Any 2026 Part D claim for a GLP-1 for a covered condition makes a person ineligible for Bridge, so reversing those claims would shift costs from the plan to the program. For a company counting on continued patient uptake, how these rules are enforced matters because it shapes who ends up in which program. The signal is early, but it is worth watching how CMS frames the review in the coming weeks.
Novo Nordisk, Lilly's chief rival in the GLP-1 market, was hit by a data breach traced to stolen GitHub access tokens. A hacking group called FulcrumSec says it got in with a leaked GitHub token and released more than 1 terabyte of data after Novo refused to pay. The breach highlights a risk that has nothing to do with drug demand or regulatory audits: the technical infrastructure that supports these companies as they scale. Novo has not commented publicly, but the incident is a reminder that as GLP-1 manufacturers grow into complex international operations, the code and systems behind them become bigger targets. For investors weighing Cramer's enthusiasm about Lilly against the risks facing Novo, this breach adds a concrete data point about how exposed these companies are becoming as their operations expand.
Beyond any single company, a broader debate is playing out among analysts: whether weight-loss drugs or artificial intelligence will reshape the economy first. Those focused on GLP-1 drugs point to potential shifts in healthcare costs and consumer spending as more people use these drugs long-term. Those focused on AI point instead to labor markets, arguing that automation could change which jobs exist faster than any drug changes health outcomes. Cramer's comments on Lilly and the operational challenges facing Novo both speak to one side of that debate, since both companies are central to the case for GLP-1 drugs as an economic force.
While analysts debate the macro effects of GLP-1 drugs, new research published today looked at a much more personal question for patients: does Ozempic use have any connection to hair loss? The research does not settle the question definitively, Hair loss was reported in Wegovy's trials and is on its label. This new study was a genetic analysis of more than 205,000 people that found a small link between GLP-1 receptor genes and male pattern baldness, and it did not study people taking the drugs. Anyone concerned about hair loss while taking Ozempic should raise it with their prescriber, since individual factors vary and a single study is not a substitute for that conversation. The research is a reminder that side-effect profiles for these drugs are still being filled in even as usage grows.
Taken together, today's stories give readers two different views of the same trend: one focused on markets and access, the other on the everyday experience of taking these drugs. Investors weighing Cramer's confidence in Lilly should also track how CMS's audits of Part D plans around the GLP-1 Bridge program unfold, since it could affect patient access at scale. Patients already using Ozempic or similar drugs should keep an open conversation going with their prescriber about any side effects they notice, including hair loss. GLP-1 drugs are moving from a niche treatment into a mainstream part of the economy, and that shift brings both opportunity and scrutiny in equal measure.
Sources
Insider Monkey: Eli Lilly (LLY) GLP-1 Growth Made It a Core Running Back Stock for Jim Cramer
BankInfoSecurity: Novo Nordisk Data Breach Tied to Stolen GitHub Access Tokens
NZ Herald: Weight-loss drugs v AI: Which one will reshape the economy first
Vice: Does Ozempic Really Make You Lose Your Hair? Here's What New Research Suggests
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.